In this free webinar, learn about defining unsuitable subjects and the impact to clinical trial outcomes. The featured speakers will discuss the Clinical Surveillance and Training (CST)'s approach to eligibility review: benefits and outcomes. Attendees will learn how eligibility review is perceived by sites and sponsors.
TORONTO, May 31, 2023 /PRNewswire-PRWeb/ -- Clinical trials have a high failure rate, even for those compounds that have demonstrated efficacy in Phase 2 in the target population. CNS trials are associated with some of the highest failure rates and pose unique challenges. Clinical trials in CNS/neuroscience are complex and prone to producing uninterpretable or ambiguous results. This can have grave effects on the development of potentially effective treatments — leading to program delay or cancellation, as well as company failure. Measures that help improve clinical trial outcomes by increasing the likelihood of a clear, interpretable signal and avoiding unnecessary trial failure are therefore of great potential value.
Top reasons for trial failure are the inability to demonstrate efficacy as well as safety issues that arise during the trials. While protocols are carefully designed to enroll the appropriate subject pool, Syneos Health has found that about 10 percent of subjects considered appropriate by sites for trial inclusion, did not meet protocol criteria. The enrollment of unsuitable subjects has the potential to have a significant financial cost to sponsors as well as risk signal detection.
So how can an eligibility review enhance clinical trial outcomes?
Join experts from Syneos Health and Karuna Pharmaceuticals as they discuss their strategy implemented by Syneos Health CST (Clinical Surveillance and Training) to help sites identify suitable subjects, minimize noise, protect study investment and help obtain clearer results.
Join Dr. Stephen Brannan, MD, Chief Medical Officer, Karuna Therapeutics; Beth Eisenberg, PhD, Director, BU Ops (Scientific Director), Clinical Surveillance & Training (CST) Neurosciences, Syneos Health; Dr. Leslie Moldauer, MD, MBA, Vice President, Medical Director, Syneos Health; and Zelma Gandy-Don Sing, PhD, Lead Clinical Scientist, Syneos Health, for the live webinar on Monday, June 19, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit How Eligibility Review Can Enhance Clinical Trial Outcomes.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article